Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03945370
Other study ID # H-18033230.1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 6, 2019
Est. completion date October 1, 2020

Study information

Verified date October 2020
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

McArdle disease, glycogen storage disease type V, is a rare metabolic disease. Affected individuals are unable to utilize sugar stored as glycogen in muscle.

Investigators hypothesize that ketones can be an alternative fuel substrate for skeletal muscle when muscle glycogenolysis is blocked as in McArdle disease.

In this study investigators will investigate the immediate effects of an oral supplementation of exogenous ketone bodies (poly-hydroxybuturate) on exercise capacity in patients with metabolic myopathies, compared with a placebo drink.


Description:

McArdle disease, glycogen storage disease type V, is a rare metabolic disease caused by mutations in the PYGM gene resulting in absence of the enzyme muscle phosphorylase. Affected individuals are unable to utilize sugar stored as glycogen in muscle, leading to exercise intolerance, exercise-induced muscle pain, contractures and rhabdomyolysis, which may cause renal failure. Currently, there are no satisfactory treatment options for McArdle disease.

A key element of alleviating symptoms in McArdle disease is to provide alternative fuels for energy metabolism. Investigators hypothesize that ketones can be an alternative fuel substrate for skeletal muscle when muscle glycogenolysis is blocked as in McArdle disease.

Aim: To investigate the immediate effects of an oral supplementation of exogenous ketone bodies (poly-hydroxybuturate) on exercise capacity in patients with metabolic myopathies.

Supplement description: food supplement containing β-hydroxybuturate esters

Methods:

Study design: Placebo-controlled, single-blind, cross-over study. Inclusion: 5-8 patients with McArdle disease and 3-5 healthy controls.

Time table:

Subjects will meet to 2 test days. Subjects will be randomized using a 1:1 assignment ratio to receive either the keto-drink or placebo drink first. The oral supplement received will be blinded for the participants and the investigators. On each test day, subjects spend approximately 4 hours at the laboratory:

- Insertion of peripheral brachial venous catheters for extracting blood samples and stable isotope infusion and hydroxybutyrate infusion.

- Baseline blood sampling, medical examination, vital sign measurements, weight and height.

- Stable isotope infusion 2 hours before the cycling exercise test. Three stable isotope tracers [2,4-13C2]-D- β-hydroxybutyrate, [1,1,2,3,3-2H5]-glycerol and [6,6-2H2]-glucose solutions, are infused via a venous catheter until a steady-state is reached. The tracer infusions will continue during the cycling test. The tracers (all from Cambridge Isotope Laboratories, Andover, MA, USA) will be dissolved and injected into a solution of 0.9% saline (NaCl) through a bacterial filter.

- One Ketone or placebo drink administration 30 minutes before the exercise test

- Subjects will perform a 40 minutes cycle exercise test at a constant load corresponding to 60-70% of their VO2max (found in a screening study). During the test, subjects wear a mask for continuous gas-exchange measurements and ECG electrodes to determine VO2 and heart rate during constant load cycling (VO2const and HRconst). Blood samples will be drawn 4 times before, every 10 minutes during exercise and after exercise. During the test participants will be asked to rate perceived exertion (RPE) on a Borg scale.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date October 1, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Genetically confirmed McArdle disease or healthy control.

- Patient is willing and able to provide written informed consent prior to participation.

- Patient is ambulatory.

Exclusion criteria:

- Patient has any prior or current medical conditions that, in the judgment of the Investigator, would prevent the patient from safely participating in and/or completing all study requirements.

- Pregnancy or breastfeeding

- Patient does not have the cognitive capacity to understand/comprehend and complete all study assessments.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
ß-hydroxybuturate esters
Oral dietary supplement product containing ß-hydroxybuturate esters
Placebo drink
Oral placebo drink

Locations

Country Name City State
Denmark Copenhagen Neuromuscular Center Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Heart rate Change between visit 1 and 2 in mean heart rate during constant load cycling exercise (40 minute submaximal cycle test) 30 minuts x 2
Secondary Ketone metabolism Change between visit 1 and 2, measured with stable isotope technique during the constant load cycling test 150 minuts x 2
Secondary Carbohydrate metabolism Change between visit 1 and 2, measured with stable isotope technique during the constant load cycling test 150 minuts x 2
Secondary Fat metabolism Change between visit 1 and 2, measured with stable isotope technique during the constant load cycling test 150 minuts x 2
Secondary Indirect calorimetry Changes in oxidation rates at visit 1 and visit 2, measured via indirect calorimetry before and during exercise 30 minuts x 2
Secondary Perceived exertion Changes in perceived exertion beween visit 1 and 2 during the cycle test 30 minuts x 2
Secondary Blood ketone Changes in ketone bodies in the blood between visit 1 and 2, measured at both before, during and at end exercise. 150 minuts x 2
Secondary Insulin Insulin changes between visit 1 and 2 measured before, during and at end exercise. 30 minuts x 2
Secondary Metabolites changes between visit 1 and 2 30 minuts x 2
See also
  Status Clinical Trial Phase
Completed NCT04349566 - Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
Enrolling by invitation NCT03211923 - Muscle Relaxation in Myopathies With Positive Muscle Phenomena
Completed NCT03112889 - Sodium Valproate for GSDV Phase 2
Completed NCT04694547 - Ketogenic Diet Survey in Patients With McArdle Disease (GSDV)
Completed NCT03843606 - Modified Ketogenic Diet in Patients With McArdle Disease Part A N/A
Recruiting NCT04929002 - Carbon-13 Magnetic Resonance Spectroscopy in Glycogen Storage Diseases
Completed NCT04226274 - A Study of the Safety of REN001 in Patients With McArdle Disease Phase 1
Completed NCT04044508 - Modified Ketogenic Diet in Patients With McArdle Disease Part B N/A
Recruiting NCT05943678 - Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study.